Vanguard Group’s Allena Pharmaceuticals ALNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,682,145
| Closed | -$512K | – | 4625 |
|
|
2022
Q2 | $512K | Buy |
2,682,145
+100,952
| +4% | +$15.6K | ﹤0.01% | 4288 |
|
|
2022
Q1 | $597K | Sell |
2,581,193
-709,562
| -22% | -$294K | ﹤0.01% | 4353 |
|
|
2021
Q4 | $1.95M | Buy |
3,290,755
+1,283,724
| +64% | +$1M | ﹤0.01% | 4046 |
|
|
2021
Q3 | $1.81M | Buy |
2,007,031
+45,887
| +2% | +$44.9K | ﹤0.01% | 4091 |
|
|
2021
Q2 | $2.55M | Buy |
1,961,144
+809,035
| +70% | +$980K | ﹤0.01% | 3897 |
|
|
2021
Q1 | $1.6M | Buy |
1,152,109
+550,562
| +92% | +$917K | ﹤0.01% | 3912 |
|
|
2020
Q4 | $770K | Buy |
601,547
+273,821
| +84% | +$382K | ﹤0.01% | 3891 |
|
|
2020
Q3 | $485K | Sell |
327,726
-90,897
| -22% | -$128K | ﹤0.01% | 3825 |
|
|
2020
Q2 | $661K | Sell |
418,623
-13,971
| -3% | -$23.5K | ﹤0.01% | 3704 |
|
|
2020
Q1 | $417K | Hold |
432,594
| – | – | ﹤0.01% | 3709 |
|
|
2019
Q4 | $1.18M | Hold |
432,594
| – | – | ﹤0.01% | 3595 |
|
|
2019
Q3 | $1.71M | Sell |
432,594
-35,596
| -8% | -$153K | ﹤0.01% | 3499 |
|
|
2019
Q2 | $1.91M | Sell |
468,190
-53,441
| -10% | -$292K | ﹤0.01% | 3492 |
|
|
2019
Q1 | $3.66M | Buy |
521,631
+96,401
| +23% | +$699K | ﹤0.01% | 3253 |
|
|
2018
Q4 | $2.32M | Buy |
425,230
+75,411
| +22% | +$650K | ﹤0.01% | 3329 |
|
|
2018
Q3 | $3.76M | Buy |
349,819
+7,400
| +2% | +$81.3K | ﹤0.01% | 3328 |
|
|
2018
Q2 | $4.46M | Buy |
342,419
+120,047
| +54% | +$1.73M | ﹤0.01% | 3248 |
|
|
2018
Q1 | $2.45M | Buy |
222,372
+36,179
| +19% | +$302K | ﹤0.01% | 3389 |
|
|
2017
Q4 | $1.87M | Buy |
+186,193
| New | +$2.29M | ﹤0.01% | 3447 |
|
Other funds holding ALNA
Vanguard Group's ALNA Position: Q3 2022 in Review
Vanguard Group sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 2,682,145 shares — an estimated $512K sold.
Vanguard Group first reported a position in ALNA in Q4 2017 and held it in 19 quarters. The position peaked at $4.46M in Q2 2018. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.
- Vanguard Group reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Vanguard Group sold 2,682,145 Allena Pharmaceuticals shares in Q3 2022, an estimated $512K.
- Vanguard Group first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 19 quarters.
- Vanguard Group's Allena Pharmaceuticals position peaked at $4.46M in Q2 2018.
- 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.
Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.